Rimegepant in Real-World Migraine Prevention

The therapeutic management of migraines has undergone a seismic shift over the past decade. The addition of calcitonin gene-related peptide (CGRP) pathway-targeted therapies—starting with parenteral monoclonal antibodies (anti-CGRP mAbs) and expanding to small-molecule CGRP receptor antagonists (gepants)—has provided clinicians with highly targeted, mechanism-based interventions. While phase II and III randomized controlled trials (RCTs) established the baseline efficacy and safety of oral rimegepant (75 mg every other day) for migraine prevention, clinical trial cohorts rarely mirror the real-world complexity encountered in routine practice. RCTs typically exclude or underrepresent individuals with extensive prior treatment failures, complex medical comorbidities, severe medication overuse, or previous exposure to biological CGRP inhibitors.

Introduction: Key Findings from the Multicenter GEMA Project

The preventive management of migraine has been transformed by therapies targeting the calcitonin gene-related peptide (CGRP) pathway. Following parenteral anti-CGRP monoclonal antibodies (mAbs), small-molecule CGRP receptor antagonists (gepants) introduced an oral, mechanism-based therapeutic strategy. While pivotal Phase II/III randomized controlled trials (RCTs) established the efficacy and safety of oral rimegepant (75 mg every other day) for episodic migraine prevention, clinical trial cohorts rarely mirror the real-world complexity seen in daily clinical practice. Pivotal trials typically exclude individuals with extensive prior treatment failures, multiple medical comorbidities, medication overuse, or prior exposure to biological CGRP inhibitors.

To address this knowledge gap, the GEMA (GEpants in MigrAine) Project—a prospective, multicenter observational cohort study across nine tertiary Headache Units in Spain—evaluated the effectiveness, safety, and predictors of response to rimegepant in 150 treatment-experienced patients followed for up to 6 months. Fulfilling International Headache Society (IHS) Level 1 data quality standards, this study offers vital guidance for structuring preventive treatment algorithms.

Why It Matters

The main clinical significance of the GEMA project rests on its demonstration that the therapeutic efficacy of rimegepant observed in controlled trials translates into real-world effectiveness among highly treatment-resistant patients. In routine practice, headache specialists regularly care for patients who have cycled through multiple traditional oral preventives (e.g., beta-blockers, topiramate, amitriptyline, flunarizine) as well as procedural or biologic interventions without achieving durable relief.

Real-World Effectiveness in High-Burden, Resistant Populations

The GEMA cohort represented an exceptionally refractory population:

• Median Prior Failures: 6 prior preventive classes (IQR = 4–8)
• Prior Procedural Failures: 54.7% (n = 82) had failed prior OnabotulinumtoxinA (BoNT-A) treatment
• Prior Biologic Failures: 39.3% (n = 59) had failed prior anti-CGRP monoclonal antibodies
• Baseline Medication Overuse: Present in 40.0% (n = 60) of patients

Primary & Secondary Efficacy Metrics at 3 Months (N = 150)

Despite this extensive treatment failure history, oral rimegepant produced statistically significant and clinically meaningful reductions across all primary and secondary endpoints within 3 months in participants:

• Monthly Headache Days (MHD): Decreased from a baseline median of 12.0 days (IQR = 10–15) to 7.5 days (IQR = 5–15) at 3 months (p < 0.001), representing a 37.5% reduction in total headache burden (mean reduction of -3.51 days)
• Monthly Migraine Days (MMD): Dropped from a baseline median of 10.0 days (IQR = 8–12) to 6.0 days (IQR = 3–10) at 3 months (p < 0.001), representing a 40.0% reduction (mean reduction of -2.89 days)
• Categorical Response Rates:
• ≥ 30% Reduction: Achieved by 51% of patients for both MHD and MMD
• ≥ 50% Response (Good): Achieved by 36% for MHD and 43% for MMD
• ≥ 75% Response (Excellent): Achieved by 15% for MHD and 20% for MMD
• Full Remission (100% MMD Reduction): Achieved by 11% (n = 16) of patients at 3 months

Exploratory 6-Month Efficacy & Disease Reversion (N = 64)

In the patient subset reaching 6 months of continuous therapy, therapeutic gains expanded further:

• Median MHD dropped to 6.0 days, and median MMD dropped to 5.0 days
• The ≥50% MMD responder rate increased to 58%, while the ≥ 75% responder rate reached 31%, and 16% maintained complete MMD remission
• Reversion from Chronic to Episodic Migraine: Rimegepant therapy induced a progressive conversion from chronic migraine (CM) to episodic migraine (EM). In the overall cohort, episodic migraine increased from 70.7% at baseline to 74.0% at 3 months and 81.3% at 6 months. In the prior anti-CGRP mAb failure subgroup, episodic status rose from 49.3% at baseline to 70.4% at 6 months.

Impact on Functional Disability & Affective Comorbidities

In addition to reducing attack frequency, rimegepant delivered significant improvements in patient-reported disability and psychological burden:

• Headache Impact Test (HIT-6): Median HIT-6 scores decreased significantly from 64.5 at baseline to 59.5 at 3 months (p < 0.0001).
• Mood & Anxiety Metrics (HADS): Reductions in Hospital Anxiety and Depression Scale scores (HADS-A and HADS-D) were significantly greater among clinical responders (≥ 50% reduction) compared to non-responders. This indicates that affective improvements are secondary to successful headache burden reduction rather than a direct psychotropic effect.
• Insomnia Severity Index (ISI): Sleep disturbance scores remained stable across responders and non-responders, suggesting that sleep architecture in chronic headache syndromes may require independent clinical intervention.

Who It Affects

Understanding which patient phenotypes derive the greatest benefit from rimegepant—and which exhibit relative resistance—is essential for personalized headache management. The GEMA study performed detailed univariable and multivariable modeling to evaluate baseline clinical characteristics as predictors of outcome.

To optimize clinical patient selection, the GEMA study conducted multivariable analyses to identify independent predictors of treatment response.

Patient Stratification & Predictors of Response

The Gradient of Refractoriness: Prior Monoclonal Antibody Failures

A central finding of the GEMA trial is the relationship between the number of prior failed anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and rimegepant responsiveness:

1. mAb-Naïve to 2 Prior Failed mAbs: Patients who were mAb-naïve or had failed 1 or 2 prior monoclonal antibodies achieved clinically meaningful reductions in MHD and MMD \[source: 1\]. In fact, 59% of patients with prior mAb exposure attained an excellent (≥ 75%) MHD response at 3 months. This demonstrates that prior biologic failure does not preclude a strong clinical response to oral agents.
2. 3 or More Prior Failed mAbs: Patients who had failed 3 or 4 prior anti-CGRP mAbs exhibited marked attenuation of treatment response, higher baseline headache frequency (median MHD = 30 in the 4-mAb subgroup), and persistent medication overuse. Those with 4 prior mAb failures demonstrated no reduction in MHD.

This physiological pattern supports a continuum of progressive clinical refractoriness rather than target-specific receptor resistance. Multiple CGRP-targeted failures reflect entrenched central sensitization, structural disease chronification, and activation of non-CGRP nociceptive pathways, rather than simple receptor insensitivity.

What Changes

The real-world findings from the GEMA project support several key shifts in daily clinical practice and treatment protocols:

Clinical Practice Implications & Therapeutic Sequencing

A. Reposition Rimegepant Earlier in the Treatment Algorithm

Traditionally, novel CGRP-targeted preventives were reserved as last-line options for refractory chronic patients. However, multivariable modeling demonstrates that lower baseline disease burden, episodic migraine status, and fewer prior preventive failures independently predict greater treatment success. Delaying rimegepant until a patient has failed multiple monoclonal antibodies and developed chronic medication overuse significantly lowers the likelihood of achieving full remission. Clinicians should consider initiating rimegepant earlier after conventional oral treatment failure.

B. Confidently Switch to Gepants Following Anti-CGRP mAb Failure

A common clinical dilemma is whether switching to an oral CGRP receptor antagonist is effective after a patient has failed an anti-CGRP monoclonal antibody. The GEMA study confirms that switching is clinically viable: 43% of the cohort achieved a ≥ 50% MMD reduction, with strong efficacy maintained in patients with 1–2 prior mAb failures. Differences in molecular pharmacokinetics, competitive receptor binding kinetics, and central nervous system penetration (crossing the blood-brain barrier) allow rimegepant to overcome non-response to monoclonal antibodies in a substantial proportion of patients.

C. Favorable Safety Profile & Medication Overuse Management

Rimegepant (75 mg every other day) offers preventive efficacy without the risk of medication overuse headache—a key advantage over traditional acute analgesics and triptans.

• Tolerability Profile: Adverse events were predominantly mild and gastrointestinal: Nausea (13% at 3m, 8% at 6m) and Constipation (8% at 3m, 8% at 6m) were most frequent. Dizziness occurred in 5% (3m) and 9% (6m).
• Discontinuation Rates: Overall treatment discontinuation was low (7% at 3 months), driven primarily by lack of effectiveness rather than adverse events. No hepatotoxicity or new safety signals emerged.

Conclusion & Actionable Takeaways for Clinicians

1. Proven Real-World Efficacy: Oral rimegepant (75 mg every other day) significantly reduces monthly headache and migraine days in treatment-experienced populations, driving a 43% ≥ 50% MMD response rate at 3 months and 58% at 6 months.
2. Effective After Biologic Failure: Prior anti-CGRP monoclonal antibody failure does not preclude rimegepant efficacy, particularly in patients with 1–2 prior mAb failures.
3. Earlier Intervention Yields Better Outcomes: Response rates decline progressively with increasing prior mAb failures and entrenched medication overuse. Introducing rimegepant earlier in the disease course maximizes clinical benefit and helps prevent disease progression to chronic migraine.

Reference

1. Gago-Veiga AB, Lopez-Rodriguez AB, Sanchez Jimenez M, Iglesias Rubio A, Montes N, Camiña Muñiz J, Dominguez Gallego M, Calle De Miguel C, Latorre G, Rodriguez-Vico J, Jaimes A, Gomez Garcia A, Urtiaga S, Gonzalez Salaices M, Dileone M, Gonzalez-García N, Porta-Etessam J, Cuadrado ML, Santos Lasaosa S, Díaz-De-Terán J, Portocarrero-Sánchez L, Casas-Limón J, Fernández-Lázaro I. Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project). Cephalalgia. 2026;46(7):1-16. doi:10.1177/03331024261462836